Table 4

Interest in learning more about medicines R&D and its specific aspects by country

GB*
Base=1528
France
Base=1000
Spain
Base=1000
Italy
Base=1000
Poland
Base=1000
Germany
1000
All
Base=6528
Pearsons’ χ2
p Value
InterestedRank
n
InterestedRank
n
InterestedRank
n
InterestedRank
n
InterestedRank
n
InterestedRank
n
InterestedRank
n
NA
Drug discovery40% (606)442% (422)151% (505)153% (531)348% (481)347% (466)246% (3011)460.8; df=5; p<0.01
Medicines safety41% (628)342% (418)151% (505)158% (582)156% (560)153% (526)149% (3219)1117.4; df=5; p<0.001
Patients’ roles and responsibilities35% (541)732% (320)842% (419)545% (446)738% (381)743% (425)439% (2532)651.1; df=5; p<0.001
Personalised medicine44% (668)240% (400)450% (501)455% (551)249% (485)242% (423)547% (3028)265.3; df=5; p<0.001
Predictive medicine46% (701)138% (381)551% (505)151% (509)448% (478)344% (443)347% (3017)244.9; df=5; p<0.0001
Design and objectives of clinical trials36% (547)637% (372)638% (384)746% (464)640% (401)639% (393)739% (2561)631.5; df=5; p<0.001
Health technology assessment39% (598)542% (417)142% (418)548% (476)545% (454)542% (419)543% (2782)521.1; df=5; p<0.001
Pharmacoeconomics29% (446)929% (292)935% (345)940% (401)934% (345)932% (316)933% (2145)942.3; df=5; p<0.001
Regulation31% (478)833% (330)736% (360)844% (437)837% (373)837% (372)836% (2350)846.0; df=5; p<0.001
  • *Participants aged 65 years and older removed from Great Britain (GB) sample to ensure that all countries were comparable by age.

  • NA, not available.